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Abstract
Acquired mutations are pervasive across normal tissues. However, our understanding of the 
processes that drive transformation of certain clones to cancer is limited. Here we study this 
phenomenon in the context of clonal hematopoiesis (CH) and the development of therapy-related 
myeloid neoplasms (tMN). We find mutations are selected differentially based on exposures. 
Mutations in ASXL1 are enriched in current or former smokers, whereas cancer therapy with 
radiation, platinum and topoisomerase II inhibitors preferentially selects for mutations in DNA 
damage response (DDR) genes (TP53, PPM1D, CHEK2). Sequential sampling provides definitive 
evidence that DDR clones outcompete other clones when exposed to certain therapies. Among 
cases where CH was previously detected, the CH mutation was present at tMN diagnosis. We 
identify the molecular characteristics of CH that increase risk of tMN. The increasing 
implementation of clinical sequencing at diagnosis provides an opportunity to identify patients at 
risk of tMN for prevention strategies.
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The multistage model of carcinogenesis suggests that the successive acquisition of somatic 
mutations predates cancer development1. Each mutation contributes to a clone’s fitness 
advantage, resulting in clonal expansions that culminate in malignant transformation, in a 
process that parallels Darwinian evolution2. This evolutionary process results from a 
complex interplay between the mechanisms that drive mutagenesis, the genetic targets of 
selection and the contexts in which these mutations contribute to differential clonal fitness.
Systematic cancer sequencing studies have delivered a detailed understanding of the 
processes that lead to mutations, the resulting mutation signature, and the genetic drivers of 
malignant disease.3,4 However, our understanding of the evolutionary trajectories that 
underlie cancer development is primarily based on retrospective modeling of clonal 
structures observed at diagnosis5 or disease progression6. Such approaches do not allow 
characterization of the genetic and clonal dynamics of early oncogenesis. Recent sequencing 
studies of normal tissues show that acquisition of somatic mutations is pervasive with 
aging7–16. Our understanding of the environmental factors that drive a subset of these 
mutated clones towards malignant transformation is limited and largely based on in vitro and 
animal studies17–19. Progress in this regard has been challenged by the paucity of 
longitudinal genetic and clonal studies with detailed annotation of intervening exposures.
Studies of clonal hematopoiesis (CH) present a unique opportunity to study the evolutionary 
process underlying malignant transformation in blood. Non-invasive sampling enables 
acquisition of statistically powered cohorts and longitudinal samples that permit assessment 
of the transition from normal to transformed disease. Population studies show that 
individuals with CH are at increased risk of transformation to myeloid neoplasms (MN)20,21. 
However, only a small proportion of CH subjects progress to MN. Cancer patients are at 
heightened risk of subsequent therapy-related myeloid neoplasms (tMN) such as AML and 
MDS22,23. tMN was traditionally thought to develop from the mutagenic effects of cancer 
therapy23. However, recent studies show that tMN-initiating mutations can predate cancer 
therapy19, consistent with CH24. Here, we sought to characterize the relationships between 
CH and environmental exposures and determine how cancer therapy shapes patterns of 
selection that contribute towards progression to overt leukemia.
Molecular characteristics and clinical determinants of CH
Utilizing prospective targeted sequencing data (MSK-IMPACT) from 24,146 cancer patients 
representing a wide range of primary tumor types (n=56) and ages (Extended Data Table 1), 
we established a stringent variant calling and filtration workflow to detect CH variants in 
blood, with a minimum variant allele frequency (VAF) of 2% (see Methods and 
Supplementary Notes). We identified 11,076 unique CH mutations in 7,216 individuals, 
representing 30% of patients in our cohort. The median VAF of CH mutations was 5.0% 
(range, 2–78%). Among individuals with CH, 69% (n=4952) had one mutation and 31% 
(2264) had two or more. The spectrum of CH mutations followed expected patterns of 
positive selection for truncating variants and missense mutations in tumor suppressors and 
oncogenes, respectively (Supplementary Figure 1). As the design of our panel limits 
interrogation to bona fide cancer genes, we annotated each mutation on the basis of its 
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putative role in cancer pathogenesis using OncoKB25 and recurrence in an in-house dataset 
of myeloid neoplasms26–28 (see Methods). Over half of the CH mutations that we detected 
were classified as putative cancer-driver mutations (CH-PD, 52%, n=5810). Almost all CH-
PD variants (91%, n=5301) were recurrent mutations in myeloid neoplasms (CH-myeloid 
PD) (Supplementary Figure 2).
Overall, mutations in myeloid driver genes (median=0.047) and CH-PD (0.050) showed 
higher VAFs than non-myeloid (0.038) and non-PD (0.038) mutations, respectively 
(Supplementary Figure 3a-b, Extended Data Table 2). Similarly, hotspot mutations at R882 
within DNMT3A had higher VAFs compared to non-hotspot mutations, even after 
accounting for total number of mutations (Supplementary Figure 4). The VAF of mutations 
within individuals who harbored multiple mutations were higher compared to individuals 
with one mutation (Extended Data Table 2, Supplementary Figure 3c). Consistent with prior 
literature13,14,24, CH mutations were most frequently identified in DNMT3A, TET2 and 
ASXL1. Overall, 48% of CH mutations identified were in myeloid driver genes, while only 
20% of genes on the MSK-IMPACT panel are myeloid driver genes. The strong enrichment 
of myeloid variants highlights the strength of the fitness advantage imparted on 
hematopoietic stem and progenitor cells (HSPCs) by mutations in genes implicated in 
myeloid pathogenesis as compared to bona fide oncogenic mutations in other cancer driver 
genes (Supplementary Figure 2).
To assess the role of cancer therapy alongside other factors in driving selection of CH 
clones, we extracted and curated detailed clinical data for 10,138 patients who had received 
all their cancer care at Memorial Sloan Kettering (MSK) (see Supplementary Notes). These 
patients’ demographic characteristics and solid tumor primary site did not differ from those 
who received treatment outside of MSK or whose treatment information was unavailable 
(n=14,008) (Supplementary Table 1). As previously reported24, older age strongly correlated 
with the presence of CH clones in cancer patients (OR=1.9, p<10−6) (Extended Data Table 
3). CH was less common in patients of Asian ancestry relative to Caucasian descent 
(OR=0.7, p=1×10−3) (Extended Data Table 3), consistent with recent reports 29.
Overall, a total of 5,978 patients (59%) were exposed to cancer therapy (including cytotoxic 
therapy, radiation therapy, targeted therapy and immunotherapy) prior to blood draw 
(Extended Data Figure 1), whereas 4,160 (41%) were treatment-naive. Patients who had 
received prior cancer treatment were more likely to have CH compared to treatment-naive 
patients at time of testing (OR=1.3, p=1×10−6). The same was true for current and former 
smokers (OR=1.1, p=5×10−3), and effect sizes were similar between current (n=729, 
OR=1.2, p=0.10) and former smokers (n=4260, OR=1.1, p=8×10−3). The number of CH 
mutations in each patient was positively associated with cancer therapy and smoking, and 
clone size was also positively associated with smoking (Extended Data Tables 2, 4). The 
association between age, therapy and CH was stronger for CH-PD compared to mutations 
not known to be putative cancer drivers (Extended Data Table 2). All subsequent analyses 
were limited to CH-PD.
The odds of having CH among cancer patients differed by primary tumor type even after 
adjustment for age (Extended Data Figure 2). The overall mutational spectrum of CH was 
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similar across cancer types, with the exception of DDR gene mutations being more frequent 
in patients with ovarian and endometrial cancers. This enrichment was most striking for 
mutations in PPM1D, which were found in 13% of patients with ovarian cancer and 7% of 
patients with endometrial cancer as compared to <5% in other cancer subgroups (Extended 
Data Figure 3). However, among patients who received no cancer therapy prior to blood 
draw, 8% of women with ovarian cancer and 0% of women with endometrial cancer had CH 
in PPM1D, suggesting that differences in the spectrum of CH mutations across tumor type 
could be explained by interactions with specific classes of cancer therapy and/or specific 
oncologic context.
Clinical parameters shape the fitness landscape of CH
We next sought to determine how specific external exposures might influence the fitness 
landscape of CH mutations and found that age, treatment and smoking correlated with 
specific molecular subtypes of CH (Figure 1a-b, Supplementary Figure 5). For example, 
mutations in the spliceosome genes SRSF2 and SF3B1 were less common in our cohort 
relative to other CH mutations, but showed the strongest association with age (ORSRSF2 = 
3.6, q (FDR-corrected p-value)=7×10−6; ORSF3B1 = 5.0, q=<10−6) (Figure 1b-c). Overall, in 
tests of heterogeneity, DNMT3A showed significantly weaker associations with age than 
other mutations, including spliceosome genes (Supplementary Figure 5). CH mutations in 
the DDR genes TP53, PPM1D and CHEK2 were most strongly associated with prior 
exposure to cancer therapy (ORTP53 = 2.8, q=2×10−4; ORPPM1D = 4.3, q=<10−6; ORCHEK2 
=4.5, q= 6×10−6, Figure 1c). Besides differences in the frequency of DDR mutations, CH 
mutational features were otherwise similar between treated and untreated individuals 
(Supplementary Figure 6). Mutations in ASXL1 were significantly associated with smoking 
history (OR=2.5, q=1×10−4, Figure 1c). Current smokers had a stronger association with CH 
in ASXL1 (OR=3.1, p=1×10−3) compared to former smokers (OR=2.4, p=1×10−4) although 
the OR did not significantly differ (p=0.4). While CH was more frequent overall among 
patients who received cancer-specific therapy, CH defined by mutations in epigenetic 
modifiers (DNMT3A, TET2) or splicing regulators (SRSF2, SF3B1, U2AF1) was not 
strongly affected by exposure to therapy (Figure 1b-c). Together, these observations provide 
evidence that the relative fitness of acquired mutations in HSPCs is modulated by 
environmental factors such as cancer treatment, smoking or the aging microenvironment in a 
gene-dependent manner.
Given the variety of cancer therapies, different therapeutic classes may impart distinct 
effects on CH. In our study, subjects were exposed to 490 different agents (Supplementary 
Notes and Supplementary Table 2). To this point, we found evidence of heterogeneity in the 
strength of association between class agent and CH gene mutations. For example, of all 
treatment modalities, external beam radiation therapy (OR=1.4, p<10−6), cytotoxic 
chemotherapy (OR=1.2, p=2×10−3) and radionuclide therapy (OR=1.6, p=0.01) were most 
strongly associated with CH-PD (global test of heterogeneity phet=0.03). With respect to 
subclasses of cytotoxic therapy, CH-PD was most strongly associated with prior exposure to 
topoisomerase II inhibitors (OR=1.3, p=0.01) and platinum agents (OR=1.2, p=0.02), and of 
the platinum agents, carboplatin (OR=1.4, 0.001) was associated with CH, unlike cisplatin 
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(OR=1.1, p=0.10) and oxaliplatin (OR=0.98, p=0.88) (Figure 2a). Targeted therapies and 
immunotherapeutic agent exposure were not significantly associated with CH (Figure 2a).
Associations with therapy exposure also varied by gene.—Mutations in PPM1D 
were most strongly associated with prior exposure to platinum (OR=3.2, q<10−6) or 
radionuclide therapy (OR=6.2, q=7×10−6) and also showed associations with topoisomerase 
II inhibitors (OR=2.0, q=0.002), taxanes (OR=1.8, q=0.003), topoisomerase I inhibitors 
(OR=1.7, q=0.002) and external beam radiation therapy (OR=1.8, q=0.04) (Figure 2b). 
Mutations in TP53 were associated with prior platinum (OR=2.1, q=0.03), radiation therapy 
(OR=1.8, q=0.04) and taxane (OR=1.9, q=0.05) exposure, whereas CHEK2 was associated 
with platinum (OR=2.4, q=0.02) and topoisomerase II inhibitors (OR=2.2, q=0.02) (Figure 
2b). The strength of the association between DDR CH and cytotoxic therapy differed by 
cytotoxic therapy subclass (p=4×10−6) and platinum subclass (p=0.03).
To evaluate whether treatment dose modulated these relationships, we calculated each 
patient’s relative cumulative exposure to specific therapy classes (see Supplementary Notes 
and Supplementary Figure 7). Increasing exposure to platinum chemotherapy was associated 
with CH-PD (p-trend=0.04). Among platinum agents, CH-PD was associated with higher 
cumulative doses of carboplatin (p-trend=3×10−5) and cisplatin (p-trend=0.04) (Figure 2c). 
Evidence of dose-response further supports a possible causal relationship between the 
associated exposures and CH.
Clonal dynamics of CH in response to cancer therapy
Our retrospective analysis suggests that exposure to cancer therapy results in a higher 
likelihood of CH, particularly in patients with mutations in DDR genes, following exposure 
to specific therapies. To definitively characterize how treatment affects mutational 
presentation and clonal dominance of CH across time, we collected sequential blood 
samples from 525 patients with solid tumors (median sampling interval time = 23 months, 
range: 6–53 months), of whom 61% received cytotoxic therapy or external beam radiation 
therapy and 39% received either targeted or immunotherapy or were untreated (see Methods 
and Supplementary Figure 8). None of these patients developed secondary hematologic 
malignancies during follow-up. Of these patients, 389 (74%) had CH, defined as a mutation 
present at a VAF of ≥2%, at the time of first sampling. The majority of CH mutations were 
present at both time points (n=590/620, 95%), allowing us to examine how clones evolved in 
the presence or absence of therapy and whether the clone-defining mutations influenced 
these trajectories.
We found evidence of both positive and negative changes in clone size across treatment 
modalities (Figure 3a). Among mutations detected at both time-points, the majority (62% 
(n=367) of CH mutations remained stable, 28% (n=164) had evidence of growth, and 10% 
(n=59) decreased in clonal size. Among patients receiving external beam radiation therapy 
or cytotoxic therapy, growth was most pronounced for CH with mutations in DDR genes 
TP53, CHEK2 and PPM1D (Figure 3b-c). Similar to our retrospective series, increasing 
cumulative exposure to these therapies resulted in faster clone growth in patients whose CH 
was defined by DDR mutations (Figure 3d). We did not see evidence of a significant 
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association between change in VAF and time from end of cytotoxic therapy to the second 
blood sampling. Future studies with sequential sampling before, during and after therapy 
will be needed to characterize the kinetics of CH. Patients with multiple mutations exhibited 
faster CH growth30 as compared to those with one mutation (p=0.03) irrespective of 
mutation type and treatment status (Supplementary Figure 9). This likely reflects the greater 
competitive advantage of a subset of clones harboring multiple mutations, although this 
cannot be determined with certainty in the absence of single-cell sequencing. The proportion 
of patients with newly detected mutations among those who received interval cytotoxic/
radiation therapy (4%, n=13) was non-significantly higher as compared to those who did not 
(1%, n=2, p=0.06) (Supplementary Figure 10). Thus, in addition to therapy selecting for CH, 
therapy may have mutagenic effects on HSPCs.
Many parameters likely influence evolutionary trajectories of emerging CH clones. To study 
competing clonal dynamics in patients, we identified 34 subjects in our prospective serial 
sampling series with one mutation in a DDR gene and one in a non-DDR gene (Figure 3e). 
The presence of these distinct classes of gene mutations within the same patient controls for 
any confounding parameters. In patients receiving interval cytotoxic therapy or radiation 
therapy, CH clones with DDR mutations grew faster compared to clones with other CH 
mutations in the same patient. However, the reverse was true in untreated patients: clones 
with mutations in non-DDR CH genes (e.g. DNMT3A) outcompeted clones with DDR 
mutations (Figure 3e). In summary, our serial sampling data provide direct evidence in 
patients that cancer therapy selects for clones with mutations in the DDR genes TP53, 
PPM1D and CHEK2 and that these clones have lower competitive fitness relative to non-
DDR gene mutations in the absence of cytotoxic or radiation therapy.
Genetic and clonal evolution to tMN
Recent studies have shown that tMN-initiating mutations can predate cancer therapy19, 
challenging the traditional hypothesis that tMN develops from the mutagenic effects of 
cancer therapy31 and suggesting a relationship with CH. We hypothesized that tMN 
development is at least in part mediated by therapeutic selection of mutant clones in a gene-
dependent manner.
To study the molecular events defining progression of CH to tMN, we analyzed 35 cases for 
which paired samples were available at the time of molecular profiling for primary cancer 
and at time of leukemic transformation for tMN (median inter-sampling time of 24 months, 
range:5–90 months) (Supplementary Table 3). We called mutations present at a VAF of ≥2% 
in at least one time-point. We detected disease-defining events at time of tMN in 34 patients. 
Strikingly at least one of these mutations was present at the time of CH (with at least one 
supporting read) in 19 patients (59%), with 13 (41%) harboring two or more. In all of these 
cases, the CH mutation was present at the time of tMN diagnosis (Extended Data Figure 4). 
However, these mutations are unlikely sufficient for leukemic transformation. In 91% of 
cases, transformation was associated with acquisition of additional somatic mutations, 
including chromosomal aneuploidies or mutations in genes (e.g. FLT3, KRAS, NRAS) 
known to drive late progression to myeloid disease27,32–34 (Supplementary Figure 11).
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Nearly half (n=14, 40%) of the tMN patients had mutations in TP53. Overall, 10/14 TP53 
mutations were detectable at time of CH testing. Of these, four cases had a concomitant 
TP53 mutation and another non-DDR mutation at time of CH. In agreement with 
prospective serial sequencing, in the presence of therapy the TP53 clone had consistently 
attained dominance by the time of tMN (Extended Data Figure 4). At transformation, in 
12/13 (92%) cases with available karyotype, TP53 mutations co-occurred with isolated 
chromosomal aneuploidies or complex karyotype. This provides a direct mechanistic link, 
whereby cells carrying mutations in TP53 are positively selected when exposed to oncologic 
therapy and attain clonal dominance with further genetic diversification, such as the 
acquisition of chromosomal aneuploidies.
Clinical implications of CH in cancer patients
Based on the direct evidence that CH mutations lead to tMN transformation in our paired 
sample data, we sought to identify risk factors associated with tMN. By combining patient 
data from our cohort with detailed clinical histories and three previously published 
studies35–37, we created a cohort of 9,437 cancer patients exposed to cancer therapy, of 
whom 75 developed tMN (Supplementary Table 2, see Supplementary Notes). Cause-
specific Cox proportional hazards analysis (Supplementary Table 2) showed that CH present 
at a VAF of >2% was positively associated with tMN risk (HR=6.9, p<10−6), and increased 
with the total number of mutations and clone size (Figure 4a). The strongest associations 
were observed for mutations in TP53, further validating the relevance of TP53 in tMN, and 
for mutations in spliceosome genes (SRSF2, U2AF1 and SF3B1). Future studies using error-
corrected sequencing methods will clarify the relationship between CH and tMN at VAFs 
<2%. Comparison of HRs for tMN and AML risk showed similar effect sizes 
(Supplementary Figure 12) in our cohort as in recent studies of healthy individuals30,38. 
These data suggest that the relative risk of myeloid neoplasms associated with CH and 
related parameters (gene, VAF and mutation number) is similar between healthy individuals 
and cancer patients.
We next sought to evaluate how CH, in combination with clinical parameters such as age 
and peripheral blood counts, might help stratify tMN risk for cancer patients. For example, 
in solid tumor patients undergoing surgical resection, adjuvant cancer therapy can improve 
overall survival by reducing cancer recurrence. However, in some situations, the absolute 
survival benefit of adjuvant therapy is modest and is countered, at least in part, by the risk 
for subsequent tMN, which is almost universally fatal, with a 5-year survival of 10%39. In 
the absence of prospective clinical studies, we performed an exploratory analysis using a 
synthetic model to quantify the absolute risk of AML/MDS following a breast cancer 
diagnosis. Using previously established methodology40,41, we combined estimates of HR 
parameters obtained from our multivariable analysis with the distribution of CH mutational 
features and blood count parameters from untreated patients at MSK and external sources to 
model the 10-year cumulative absolute AML/MDS risk distribution for women with breast 
cancer aged 50–75 in the United States. This risk model assumes a multiplicative effect of 
CH mutational features and cancer therapy on risk of tMN, based on the similarity between 
risk estimates for CH mutational features in AML that develops in individuals never exposed 
to therapy and tMN (Supplementary Figure 12). We determined how the risk distribution 
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would change with receipt of adjuvant therapy by shifting the population between receiving 
and not receiving adjuvant chemotherapy.
In our model, the majority (96%) of breast cancer patients have a low 10-year absolute risk 
(< 1%) for MN (Figure 4b) and for these patients, deferment of adjuvant chemotherapy 
would not impact their absolute MN risk (Figure 4c). However, for women at the highest 
risk of MN based on CH and blood count parameters in our synthetic model (top 1%), 
adjuvant chemotherapy increased the absolute risk of MN by approximately 9%. This would 
exceed the predicted absolute benefit in overall survival of chemotherapy in many women 
with early-stage breast cancer42. While not appropriate for clinical implementation, our 
findings may inform the design and provide a rationale for future studies to formally 
estimate the benefits of risk-adapted treatment decisions in cancer patients with CH.
DISCUSSION
Longitudinal studies of CH present a unique opportunity to study the patterns of early 
mutagenesis and the dynamics of clonal selection in the progression towards malignant 
transformation. Here, by combining epidemiologic and genetic approaches, we provide 
insights into the mechanisms that drive the transition of a normal HSPC to a cell with a 
considerably stronger proliferation advantage, and study how the ensuing trajectories are 
shaped by host and environmental exposures including age, ethnicity, smoking and cancer 
therapy. We provide evidence that the fate of CH mutations is dictated by a complex 
interplay between the inherent fitness advantage of the mutation(s) in HSPCs and parameters 
that preferentially select for specific mutations, i.e. aging for spliceosome mutations, 
smoking for mutations in ASXL1, and cancer therapy for specific genes involved in DDR 
(Extended Data Figure 5). These relationships provide insight into disease biology and may 
inform early detection and prevention strategies in cancer. We refine the relevance of CH as 
a predictor and precursor of tMN in cancer patients and show that CH mutations detected 
prior to tMN diagnosis were consistently part of the dominant clone at transformation. We 
demonstrate that cancer therapy directly favors growth of clones with mutations in genes 
such as TP53, which is associated with chemo-resistant disease and is strongly enriched in 
tMN. This provides a direct mechanistic link between genetic subtypes of CH, receipt of 
subsequent cancer therapy, and how these modulate the transition from CH to attainment of 
clonal dominance and, for a subset of cases, development of tMN.
Previous murine and in vitro modelling studies have provided evidence supporting an 
association between cancer therapy and increased fitness of DDR clones in CH. However, 
these observations have not been verified in human subjects, nor do they define how therapy 
enables the transition of CH to MN. Here we show that clones with DDR mutations are 
positively selected in the presence of cancer therapy but not in its absence. We also show 
that beyond clonal dominance the transition to tMN is most parsimoniously associated with 
the acquisition of further genetic lesions. Our detailed treatment information including agent 
class, dose and mechanism of action allowed us to refine the specificity and strength of the 
association between cancer therapy and CH and characterize distinct gene-treatment effects. 
We show that radiation therapy and cytotoxic therapy are significantly associated with CH, 
with regimens containing platinum and topoisomerase II inhibitors most strongly correlating 
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with CH in specific DDR pathway genes including TP53, PPM1D and CHEK2. Serial 
sampling before and after therapy provided clear, definitive evidence that therapy induces 
gene-specific clonal expansion, whereby clones with mutations in DDR genes outcompete 
other clones in the setting of cancer therapy, but not in its absence. Last, the dose-response 
relationships observed in both our cross-sectional arm and longitudinal study further support 
a causal relationship between platinum and CH and the cumulative effect of therapy on 
selection.
The specificity of the associations at a genetic and exposure level (i.e. therapeutic subclasses 
and agents such as carboplatin) sets a framework for future correlative and mechanistic 
studies into early oncogenesis for blood disorders. The specific mechanisms and pathways 
through which chemotherapeutic agents induce HSC injury may be agent-specific43,44. 
Further work will be needed to elucidate the mechanisms responsible for the differential 
fitness effects of cancer therapy and other environmental exposures such as smoking on CH 
both during and after exposure, and how this relates to tMN risk. Beyond the most frequent 
cancer genes surveyed here, comprehensive genome studies such as deep whole exome or 
whole genome analyses in cohorts linked to detailed registries of environmental exposures 
are warranted to uncover the full repertoire of selection in CH.
We find overlap in the types of cancer therapy associated with selection of DDR CH and 
those linked to tMN risk (carboplatin, topoisomerase II inhibitors and radiation). Selection 
of TP53 is only one mechanism driving tMN and may be distinct from the processes driving 
initiation and selection for other tMN-associated alterations including chromosomal 
aneuploidies and genomic rearrangement (i.e. MLL fusion genes). Our work adds to early 
evidence45,46 that external stressors are critical in shaping gene-dependent selection of 
clonal mosaicism. Characterization of the complex interplay between genotype, fitness 
challenges, and environmental factors will be key to understanding age-associated clonal 
mosaicism and the associated exposures that result in malignant transformation. These 
insights would provide the premise for risk stratification and prevention strategies.
Our observations provide a rationale for clinical therapeutic intervention, including the 
development of therapies aimed to target high-risk CH clones and modulation of the use of 
adjuvant systemic cancer therapy in patients at highest risk of subsequent myeloid neoplasm. 
The latter could entail deferring adjuvant cytotoxic therapy or substituting therapies shown 
to promote high-risk CH with alternative agents when clinically appropriate. We showcase 
this with a prototype synthetic model; however, development and validation of risk 
prediction models for specific clinical scenarios are needed prior to implementation. The 
realization of precision medicine is reliant upon the development of evidence-based 
guidelines that consider molecular biomarkers alongside standard clinical criteria to inform 
clinical care. The decreasing cost of prospective clinical sequencing assays and the high 
frequency of CH in cancer patients suggest that screening for CH prior to initiation of cancer 
therapy may be feasible, and may enable molecularly based early detection and interception.
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The study population included patients with non-hematologic cancers at MSKCC that 
underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an 
institutional prospective tumor sequencing protocol (ClinicalTrials.gov number, 
NCT01775072) before July 1st, 2018; all patients enrolled on this protocol provided 
informed consent. This study was approved by the MSKCC Institutional Review Board 
(IRB). A subset of patients that underwent tumor-genomic profiling as standard of care were 
not directly consented, in which case an IRB waiver was obtained to allow for inclusion into 
this study.
We extracted data on ethnicity, smoking, date of birth and cancer history through the MSK 
cancer registry. Subjects who had a hematologic malignancy diagnosed within three years 
prior to blood collection for MSK-IMPACT testing or who had an active hematologic 
malignancy at the time of blood draw were excluded. Subjects who were diagnosed with a 
hematologic malignancy less than three months following MSK-IMPACT were considered 
to have an active hematologic malignancy at the time of MSK-IMPACT and were also 
excluded. When unavailable through the cancer registry, we extracted data on ethnicity and 
smoking through structured fields in clinician medical notes if available. Subjects for which 
age was not available were excluded. Blood indices were taken from clinical labs closest to 
the date of blood collection for MSK-IMPACT, within one year before or after blood 
collection (median 0 days). The 8,810 individuals included in the previous MSK-IMPACT 
publication studying CH are included in the current manuscript. A major difference between 
the two studies, in addition to an expanded sample size, is the comprehensiveness of the 
clinical data, including therapeutic exposure data, that was obtained as detailed in the 
supplementary notes section.
Serial Sampling Cohort
In order to study the growth rate of clonal hematopoiesis mutations over time we collected 
additional blood samples on patients sequenced using MSK-IMPACT for repeat CH 
mutation testing. These came from three sources: first, from 372 patients with CH in whom 
we obtained a second blood sample at least 18 months after initial MSK-IMPACT blood 
collection, second, from 21 samples from patients with clonal hematopoiesis on MSK-
IMPACT who had a blood sample banked at least 12 months prior to MSK-IMPACT testing, 
and third, from 132 samples that were taken for repeat MSK-IMPACT testing for clinical 
purposes at least six months after the first MSK-IMPACT testing irrespective of clonal 
hematopoiesis status (Supplementary Figure 8). For all patients who had sequential 
sampling data, we manually reviewed their medical records to capture receipt of cancer 
therapy received at outside institutions during the follow-up period. If subjects received 
therapy outside MSK during the follow-up period, we excluded them from analyses of dose-
response relationships since cumulative dose of therapy could not be consistently collected 
from outside records. This study was approved by the MSKCC IRB.
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Subjects had a tumor and blood sample (as a matched normal) sequenced using MSK-
IMPACT, a FDA-authorized hybridization capture-based next-generation sequencing assay 
encompassing all protein-coding exons from the canonical transcript of 341, 410, or 468 
cancer-associated genes (Supplementary Table 4). MSK-IMPACT is validated and approved 
for clinical use by New York State Department of Health Clinical Laboratory Evaluation 
Program and is used to sequence cancer patients at Memorial Sloan Kettering. Genomic 
DNA is extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue and patient 
matched blood sample, sheared and DNA fragments were captured using custom probes47. 
MSK-IMPACT contains most of the commonly reported CH genes with few exceptions. 
Earlier versions of the panel did not contain PPM1D or SRSF2. Additionally, three genes 
commonly reported to be observed in patients with malignancies, SRCAP, BRCC3 and 
ZNF318 were not included, the former two belonging to the DNA damage response 
pathway.
The blood samples in the serial sampling cohort that were obtained for repeat CH testing 
were sequenced using a comparable capture-based custom panel using 163 genes implicated 
in myeloid pathogenesis, which included the most commonly mutated genes in our MSK-
IMPACT study, with the exception of ATM. The median sequencing depth was 665X 
(range=111–1987X) which was comparable to that obtained in the blood using MSK-
IMPACT. For all subsequent analyses using the serial sampling cohort we only considered 
mutations that were present in both the initial and follow-up panel.
Variant Calling
Pooled libraries were sequenced on an Illumina HiSeq 2500 with 2×100bp paired-end reads. 
Sequencing reads were aligned to human genome (hg19) using BWA (0.7.5a). Reads were 
re-aligned around indels using ABRA (0.92), followed by base quality score recalibration 
with Genome Analysis Toolkit (GATK) (3.3–0). Median coverage in the blood samples was 
497x, and median coverage in the tumors was 790x. Variant calling for each blood sample 
was performed unmatched, using a pooled control sample of DNA from 10 unrelated 
individuals as a comparator. Single nucleotide variants (SNVs) were called using Mutect and 
VarDict. Insertions and deletions were called using Somatic Indel Detector (SID) and 
VarDict. Variants that were called by two callers were retained. Dinucleotide substitution 
variants (DNVs) were detected by VarDict and retained if any base overlapped a SNV called 
by Mutect. All called mutations were genotyped in the patient matched tumor sample. 
Mutations were annotated with VEP (version 86) and OncoKb.
Post-Processing Filters for Clonal Hematopoiesis Calling
We applied a series of post-processing filters to further remove false positive variants caused 
by sequencing artifacts and putative germline polymorphisms. We removed variants that 
were found (with a VAF of >2% at least once) in a panel of sequencing data from 300 blood 
samples obtained from persons under 20 years of age and without evidence of clonal 
hematopoiesis. We further filtered single nucleotide deletions within a homopolymer stretch 
of (≥3 base repetition) of the same deleted base pair, single nucleotide substitutions 
completing a stretch of a ≥5 bp-long homopolymer (E.g. GGCGG -> GGGGG) in-frame 
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deletions or insertions in a highly repetitive region (DUST48 algorithm score of ≥5), and 
variants with unequal proportions of forward/reverse direction supporting reads based on a 
fisher test. We performed manual review in IGV of recurrent mutations not previously 
reported in public databases. We required a variant allele fraction of at least 2% and at least 
10 supporting reads. All genotypes were calculated using sequencing reads and bases with a 
quality value of at least 20. Because somatic mutations in the blood would be expected to be 
detected in the blood but not other tissue compartments, we compared the variant allele 
fraction (VAF) of mutations in the blood compared to the matched tumor. Variant calls that 
were present in the blood with a VAF of at least twice that in the tumor or 1.5 times the VAF 
if the tumor biopsy site was a lymph node were considered somatic. This ratio was chosen 
based on minimizing sensitivity and specificity of CH calls through simulations of leukocyte 
contamination in the tumor (see Supplementary Notes and Supplementary Figures 11 and 
12). To further filter putative germline polymorphisms that passed the blood/tumor solid 
tissue ratio due to allelic imbalance in the tumor specimen, we removed any variant reported 
in any population in the gnomAD database at a frequency greater than 0.005.
Validation of Calls
To test the reproducibility of our clonal hematopoiesis mutation calling, we compared the 
mutational calling results from 1,173 samples, where the same DNA library for a blood 
sample was sequenced and analyzed twice using MSK-IMPACT. We detected 91% of 
variants in both samples using our calling criteria with a correlation coefficient of 0.98 for 
the variant allele fraction between the two calls indicating that the reproducibility of our 
calls was high. In 10 cases with CH, we obtained a second blood sample and re-sequenced 
using a custom capture based panel with unique molecular identifiers and found that this 
independent method confirmed all 18 of our CH calls using MSK-IMPACT.
Variant Annotation
Variants were annotated according to evidence for functional relevance in cancer (putative 
driver or CH-PD) and for relevance to myeloid neoplasms specifically (CH-myeloid-PD). 
We annotated variants as oncogenic in myeloid disease (CH-myeloid-PD) if they were in a 
gene hypothesized to drive myeloid/hematologic malignancies (Supplementary Table 5) and 
if they fulfilled any of the following criteria: 1) truncating variants in NF1, DNMT3A, 
TET2, IKZF1, RAD21, WT1, KMT2D, SH2B3, TP53, CEBPA, ASXL1, RUNX1, BCOR, 
KDM6A, STAG2, PHF6, KMT2C, PPM1D, ATM, ARID1A, ARID2, ASXL2, CHEK2, 
CREBBP, ETV6, EZH2, FBXW7, MGA, MPL, RB1, SETD2, SUZ12, ZRSR2 or in CALR 
exon 9; 2) translation start site mutations in SH2B3; 3) TERT promoter mutations; 4) FLT3-
ITDs; 5) in-frame indels in CALR, CEBPA, CHEK2, ETV6, EZH2; 6) any variant occurring 
in the COSMIC “haematopoietic and lymphoid” category greater than or equal to 10 times; 
7) any variant noted as potentially oncogenic in an in-house dataset of 7,000 individuals with 
myeloid neoplasm greater than or equal to 5 times. We annotated variants as oncogenic (CH-
PD) if they fulfilled any of the following criteria: 1) any variant noted as oncogenic or likely 
oncogenic in OncoKB25; 2) any truncating mutations (nonsense, essential splice site or 
frameshift indel) in known tumor suppressor genes as per the Cancer Gene Census, 
OncoKB, or the scientific literature; 3) any variant reported as somatic at least 20 times in 
COSMIC49; 4) any variant meeting criteria for CH-Myeloid-PD as above. All missense 
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variants not meeting the above criteria were individually reviewed for potential oncogenicity 
as previously described50.
Calculation of dN/dS Ratios
We used the dNdScv (https://github.com/im3sanger/dndscv) package to quantify the dN/dS 
ratios for missense and truncating mutations at the gene level as well as on the panel level. 
Due to the difference in the gene panel between different MSK-IMPACT panel versions, we 
excluded all MSK-IMPACT-341 samples and only included genes that were present on both 
MSK-IMPACT-410 and MSK-IMPACT-468 panels in the analysis. Finally, to generate the 
overall dN/dS landscape in CH, we only presented genes that reached a significance level of 
q<0.1 after multiple testing correction and contained more than 25 variants.
Modeling the Association Between CH and Prior Exposure to Cancer Therapy
We used multivariable logistic regression to evaluate for an association between clonal 
hematopoiesis (including gene and variant specific factors) and therapy, age, gender and 
smoking history. In addition to these variables, we also adjusted for time from cancer 
diagnosis to blood draw for MSK-IMPACT testing because trends in preferred oncologic 
agents vary over time and CH is known to associate with survival. We did not adjust for 
primary tumor type since we hypothesized that most of the difference in CH-PD rates 
reflected differences in treatment regimens. Indeed, among untreated patients, a global Wald 
test for differences in CH-PD prevalence by tumor type was not significant (p=0.98). 
Analyses stratified by the time since start and by completion of external beam radiation and 
chemotherapy showed no clear evidence of a time-dependence/latency between CH-PD and 
cumulative exposure to therapy. Thus, the time from start or stop of therapy was not adjusted 
for. While considering exploratory analyses, we performed multiple hypothesis correction 
using the false discovery rate (FDR) q-values for gene-specific analyses to control for 
inflation of type I error. We did not perform multiple hypothesis correction for analyses 
testing an association between subclasses of cancer therapy and CH because the association 
between cancer therapy and CH is known and our goal was to define the relative strength of 
these associations with subtypes of therapy rather than hypothesis testing. Heterogeneity p-
values to test for differences in the strength of the association between subclasses of CH and 
clinical variables were calculated through logistic regression models limited to CH-positive 
individuals testing for a difference in the odds of having CH with the mutational feature of 
interest (e.g. CH-PD) vs. having CH without the mutational feature (e.g. non-CH-PD). 
Generalized estimating equations were used to test for an association between CH VAF and 
selected clinical and mutational features among CH positive individuals accounting for 
correlation between the VAF of mutations in the same person. Ordinal logistic regression 
among CH positive individuals was used to test for an association between clinical 
characteristics and increasing CH mutation number. A test for trend between increasing 
cumulative exposure to cancer therapy and the odds of CH-PD was performed using 
multivariable logistic regression limited to individuals exposed to the therapy of interest.
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Modeling the Effect of Cancer Therapy on Mutation Growth Rate
For each mutation in each individual with sequential sequencing data available, we modeled 
the growth rate of the mutation between the two time points according to the following 
formula:
α = log V / V0 / T − T0
Where T and T0 indicates the age of the individual (in days) at the two measurement time 
points and V and V0 correspond to the VAF at T and T0 respectively. We also classified 
mutations as having increased, decreased or remained constant during the follow-up period 
based on a binomial test comparing the two VAFs. Generalized estimating equations were 
used to test for an association between exposure to cytotoxic therapy and external beam 
radiation therapy and CH growth rate adjusting for age, gender and smoking status 
accounting for correlation between the growth rate of mutations in the same person. Among 
patients with at least one mutation in a DDR CH gene and another non-DDR CH gene, we 
calculated the difference in the growth rate between mutations. When patients had more than 
two mutations in the same gene category, we used the highest growth rate for that category. 
A paired t-test was used to test for significance in the difference between growth rates of 
DDR mutations compared to non-DDR mutations within individuals who received cytotoxic 
therapy and/or external beam radiation therapy and within those who were untreated during 
the follow-up period.
Combined Analysis for AML/MDS Risk
We combined data from MSK and three previously published studies, Gillis et al., 
abbreviated MOF (n=68), Takahashi et al., abbreviated MDA (n=67), Gibson et al., 
abbreviated DFC (n=401) studying the effect of CH on tMN risk in cancer patients. We 
defined tMN as an MDS or AML diagnosed following exposure to therapeutic radiation or 
cytotoxic therapy as per the WHO criteria51. For all samples, uniform post processing filters 
were applied to ensure retention of variants in accordance with the QC standards of the 
MSK cohort including a universal 2% minimum VAF cutoff. We only included mutations 
within genes that are present on the panel from all centers and on all panel versions from 
each center (Supplementary Table 6). The only exceptions were SRSF2 which the 
IMPACT-341 sequencing panel did not cover and PPM1D which was not sequenced in 
IMPACT-341, MDA or MOF. We performed mean imputation of missing clinical data for 
blood counts. Only mutations that we classified as CH-PD were included in analyses. We 
performed univariate cause-specific Cox proportional hazards regression for the effect of 
maximum VAF, total number of CH mutations, CH in specific genes and blood count 
parameters adjusted for age and gender and stratified by study site. Interaction terms 
between study and CH were used to test for heterogeneity between studies on the effect of 
CH on tMN risk. The proportional hazards assumption was tested through visual inspection 
of residual plots and through the inclusion of time-varying covariates. We performed a 
multivariable analysis including age, gender and all variables that were significant in the 
univariate analysis with the exception of the genes not included in all studies to prevent 
reduction of sample size, PPM1D and SRSF2. Because our sample set was limited to 
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individuals who received cancer therapy, we were unable to study gene-treatment 
interactions in the risk of myeloid neoplasm. Thus, in our combined model CH and cancer 
therapy are modeled as having multiplicative effects, i.e. no multiplicative interaction on 
myeloid neoplasm risk. We think this is a reasonable assumption for an exploratory analysis 
such as the one presented in our study. Much larger studies (including solid tumor patients 
who did and did not receive any cancer therapy besides surgery) would be needed to define 
the magnitude of CH-treatment interactions.
We also combined data from two studies investigating the effect of CH on AML risk in 
healthy individuals, Abelson et al., abbreviated PMC (n=969) and Young et al., abbreviated 
WSU (n=103), with data from MSK and applied uniform processing to mutation data from 
different centers. As in the solid tumor combined analysis, the same post processing filters 
used in the main MSK cohort including a universal 2% minimum VAF cutoff were applied 
to these studies and only mutations that we classified as CH-PD were included in analyses. 
We performed a multivariable Cox regression adjusted for age and gender including the 
variables used in the multivariable tMN risk analysis in solid tumor patients.
Modeling Absolute Risk of AML/MDS
We used the iCARE R package40,41 to build a model for absolute risk of AML/MDS in 
women with breast cancer aged 50–75 in the United States (U.S) by combining 1) the 
multivariate HR estimates from our study that were significant in the univariate model 
including maximum VAF of CH, gene specific effects and peripheral blood count indexes 
(RDW, hemoglobin); 2. Age-specific AML/MDS rates in breast cancer using data provided 
by the National Comprehensive Cancer Network (NCCN)52; 3. Competing hazards for 
mortality in women with breast cancer in the U.S aged 50–75 as reported in SEER53; 4. 
Previously published HR estimates for chemotherapy on the risk of tMN in women with 
breast cancer from the NCCN52; 5. The distribution of CH VAF, number of mutations, CH 
gene and peripheral blood count indexes using our cohort of MSK solid tumor cancer 
patients aged 50–75 who were untreated prior to blood draw; 6. The proportion of women 
who receive adjuvant chemotherapy for breast cancer in the U.S from SEER53. While our 
IMPACT cohort is not representative of the general breast cancer population in the U.S, 
since the distribution of CH mutational features is largely driven by age and since we do not 
see major differences in rates of CH between gender or untreated tumor types, we believe 
that the distribution of CH mutational features in untreated solid tumor patients sequenced 
on IMPACT reasonably approximates an age-matched untreated breast cancer population. 
While blood count indexes are known to differ by sex and we chose to use the distribution of 
blood counts from the entire treatment-naive IMPACT population (both male and female) to 
capture the inter-relationship between blood count indexes and CH mutational features. 
Sensitivity analyses using the distribution of blood count parameters from female IMPACT 
patients only produced similar results. This risk model assumes an additive association on 
the log scale of CH mutational features and cancer therapy for risk of tMN. This assumption 
is supported by the similarity between risk estimates for CH mutational features between 
AML in healthy individuals never exposed to therapy and tMN (Supplementary Figure 10).
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All the statistical analyses were performed using the R statistical package (www.r-
project.org). The code used in statistical analysis is provided in the Supplementary Notes.
Extended Data
Extended Data Figure 1. Distribution of cancer therapy received prior to blood collection for 
sequencing.
A) Frequency of patients receiving systemic therapy or external beam radiation therapy by 
primary tumor type. B) Frequency of patients receiving specific classes of systemic therapy 
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by primary tumor type. C) Frequency of patients receiving top ten subclasses of cytotoxic 
therapy. Most patients (91%) who received at least one of these cytotoxic therapy classes 
received multiple classes.
Extended Data Figure 2. Association between primary tumor site and CH-PD.
Odds ratios (circle) and 95% confidence intervals for CH-PD in selected primary tumor 
types with at least 100 subjects compared to breast cancer (n=3540) in a logistic regression 
model adjusted for age. * p<0.05, ** p<0.01, *** p<0.001.
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Extended Data Figure 3. 
Proportion of patients with common CH-PD mutations by primary tumor sites. Genes 
mutated in at least 75 individuals and the top 12 primary tumor sites are shown.
Bolton et al. Page 18













Extended Data Figure 4. Variant frequencies (VAF) at time of pre-tMN testing and tMN 
diagnosis.
Plots show changes in mutational frequencies in relation to cancer therapy exposure in 19 
CH cases. Below each graph are listed treatments received prior to pre-tMN testing and the 
number of days between the end of treatment and the pre-tMN sample.
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Extended Data Figure 5. Differences in the fitness effect of CH mutations and the environment 
shape clonal dominance over an individual’s lifetime.
Conceptual graph illustrating how associations between specific exposures and CH 
mutations may shape clonal dominance over an individual’s lifetime. AML, acute myeloid 
leukemia; cyclophosph, cyclophosphamide; MDS, myelodysplastic syndrome.
Extended Data Table 1.
Clinical characteristics of solid tumor patients assessed for CH.
CH− CH+
Total 16930 (70%) 7216 (30%)
Smoking status
 Non-smoker 8979 (74%) 3086 (26%)
 Current/former 7255 (65%) 3894 (35%)
 Missing 696 (75%) 236 (25%)
Gender
 Male 7710 (70%) 3315 (30%)
 Female 9220 (70%) 3901 (30%)
Age
 0–10 324 (96%) 13 (3.9%)
 10–20 284 (96%) 13 (4.4%)
 20–30 672 (95%) 36 (5.1%)
 30–40 1398 (92%) 121 (8%)
 40–50 2757 (87%) 420 (13%)
 50–60 4490 (78%) 1298 (22%)
 60–70 4499 (64%) 2575 (36%)
 70–80 2127 (50%) 2092 (50%)
 80–90 379 (37%) 648 (63%)
Ethnicity
 White 12628 (69%) 5802 (31%)
 Asian 1274 (78%) 356 (22%)
 Black 1081 (73%) 410 (27%)
 Other 1175 (77%)  355 (23%)
 Unknown 772 (72%) 293 (28%)
Therapy
 Treated 4193 (70%) 1785 (30%)
 Untreated 3027 (73%) 1133 (27%)
 Unknown 9710 (69%) 4298 (31%)
Primary tumor subtype
Ampullary carcinoma 47 (76%) 15 (24%)
Anal cancer 38 (67%) 19 (33%)
Appendiceal cancer 128 (79%) 34 (21%)
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Biliary cancer 351 (69%) 157 (31%)
Bladder cancer 445 (62%) 267 (38%)
Breast carcinoma 2610 (74%) 930 (26%)
Cancer of unknown primary 484 (67%) 239 (33%)
Cervical cancer 91 (77%) 27 (23%)
Chondroblastoma 1 (100%) 0 (0%)
Chondrosarcoma 42 (78%) 12 (22%)
Chordoma 27 (75%) 9 (25%)
Choroid plexus tumor 3 (100%) 0 (0%)
Colorectal cancer 1625 (75%) 528 (25%)
Embryonal tumor 153 (89%) 18 (11%)
Endometrial cancer 510 (61%) 321 (39%)
Ependymomal tumor 26 (90%) 3 (10%)
Esophagogastric carcinoma 464 (70%) 196 (30%)
Ewing sarcoma 66 (89%) 8 (11%)
Gastrointestinal neuroendocrine tumor 73 (68%) 34 (32%)
Gastrointestinal stromal tumor 200 (70%) 84 (30%)
Germ cell tumor 352 (91%) 35 (9%)
Gestational trophoblastic disease 10 (77%) 3 (23%)
Glioma 834 (76%) 260 (24%)
Head and neck carcinoma 252 (69%) 111 (31%)
Hepatocellular carcinoma 134 (71%) 55 (29%)
Melanoma 612 (69%) 269 (31%)
Meningothelial tumor 52 (79%) 14 (21%)
Mesothelioma 146 (65%) 78 (35%)
Miscellaneous brain tumor 22 (85%) 4 (15%)
Miscellaneous neuroepithelial tumor 11 (65%) 6 (35%)
Nerve sheath tumor 43 (88%) 6 (12%)
Non-small cell lung cancer 2235 (63%) 1324 (37%)
Osteosarcoma 98 (90%) 11 (10%)
Ovarian cancer 411 (62%) 254 (38%)
Pancreatic cancer 964 (68%) 452 (32%)
Penile cancer 7 (78%) 2 (22%)
Pheochromocytoma 6 (86%) 1 (14%)
Pineal tumor 1 (25%) 3 (75%)
Prostate cancer 971 (65%) 523 (35%)
Renal cell carcinoma 445 (78%) 128 (22%)
Retinoblastoma 38 (95%) 2 (5%)
Salivary carcinoma 161 (76%) 52 (24%)
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Sellar tumor 53 (88%) 7 (12%)
Sex cord stromal tumor 29 (81%) 7 (19%)
Skin cancer, non-melanoma 137 (60%) 91 (40%)
Small bowel cancer 66 (77%) 20 (23%)
Small cell lung cancer 128 (60%) 84 (40%)
Soft tissue sarcoma 751 (76%) 233 (24%)
Thymic tumor 35 (70%) 15 (30%)
Thyroid cancer 267 (62%) 165 (38%)
Uterine sarcoma 124 (73%) 46 (27%)
Vaginal cancer 10 (67%) 5 (33%)
Wilms tumor 23 (96%) 1 (4.2%)
Unknown 75 (69%) 34 (31%)
Extended Data Table 2.
Association between variant allele fraction (VAF) of CH 
mutations and clinical characteristics.
Generalized estimating equations were used to test for association between VAF of CH 
mutations (among those with a mutation) and selected clinical and mutational features, 
accounting for correlation between the VAF of mutations in the same person. Age expressed 
in decile.
Variable (ref) OR 95% CI p
Age - 1 1–1.1 0.0011
Ethnicity (white) Asian 1 0.94–1.2 0.42
Black 0.9 0.82–1 0.053
Other 0.93 0.83–1 0.24
Unknown 0.92 0.8–1.1 0.22
Smoking status (non-smoker) Smoker 1.1 1.1–1.2 0.000023
Therapy (untreated) Treated 1 0.96–1.1 0.8
PD status (Non-PD non-myeloid) Myeloid PD 1.3 1.3–1.4 < 1 × 10−6
Non-myeloid PD 1.3 1.2–1.5 0.000052
Non-PD myeloid 0.99 0.92–1.1 0.8
Number of mutations (1) ≥ 2 1.1 1.1–1.2 0.0000038
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Extended Data Table 3.
Association among clinical characteristics and CH 
mutational characteristics.
Myeloid PD, genes mutated in myeloid neoplasms; non-myeloid, genes not linked to 
myeloid neoplasms; myeloid PD, variants known to be myeloid drivers or putative somatic 
driver mutations in myeloid neoplasms; myeloid non-PD, mutations within genes linked to 
myeloid neoplasms but that are not putative drivers; non-myeloid PD, mutations that are 
putative somatic driver mutations of cancer in genes not linked to myeloid neoplasms; non-
myeloid non-PD, mutations within genes not linked to myeloid neoplasms that are not 
putative drivers of cancer. Associations were evaluated using multivariable logistic 
regression models to generate heterogeneity p-values. Sensitivity analyses restricted to 
individuals with only one mutation yielded similar results. Age expressed in decile.
Variable (reference) OR 95% CI p
Age - 1 1–1.1 0.0011
Ethnicity (white)
Asian 1 0.94–1.2 0.42
Black 0.9 0.82–1 0.053
Other 0.93 0.83–1 0.24
Unknown 0.92 0.8–1.1 0.22
Smoke (non-smoker) Smoker 1.1 1.1–1.2 0.000023
Therapy (untreated) Treated 1 0.96–1.1 0.8
PD status (non-PD non-myeloid)
Myeloid PD 1.3 1.3–1.4 < 1 × 10−6
Non-myeloid PD 1.3 1.2–1.5 0.000052
Non-PD myeloid 0.99 0.92–1.1 0.8
Number of mutations (1) ≥ 2 1.1 1.1–1.2 0.0000038
Extended Data Table 4.
Association between CH mutation number and clinical 
characteristics.
Ordinal logistic regression was used to test for association between clinical characteristics 
and mutation number in patients with clonal hematopoiesis in a multivariable model. Age 
expressed in decile.
Variable (reference) OR 95% CI p
Age (0–10) > 10 2.3 2–2.6 < 1 × 10−6
Gender (male) Female 1.1 0.94–1.3 0.2
Ethnicity (white) Non-white 0.83 0.67–1 0.087
Smoke (non-smoker) Smoker 1.2 1–1.4 0.027
Therapy (untreated) Treated 1.2 1.1–1.5 0.011
Bolton et al. Page 23














Refer to Web version on PubMed Central for supplementary material.
Authors 
Kelly L Bolton1, Ryan N Ptashkin2,*, Teng Gao3,*, Lior Braunstein4, Sean M Devlin5, 
Daniel Kelly6, Minal Patel7, Antonin Berthon3, Aijazuddin Syed2, Mariko Yabe8, 
Catherine C. Coombs9, Nicole M. Caltabellotta7, Mike Walsh10, Kenneth Offit10, 
Zsofia Stadler11, Diana Mandelker2, Jessica Schulman7, Akshar Patel7, John 
Philip12, Elsa Bernard3, Gunes Gundem3, Juan E Arango Ossa7, Max Levine13, 
Juan S Medina Martinez13, Noushin Farnoud7, Dominik Glodzik3, Sonya Li10, Mark 
E Robson10, Choonsik Lee14, Paul D P Pharoah15,16, Konrad H Stopsack10, 
Barbara Spitzer13, Simon Mantha17, James Fagin10,18, Laura Boucai19, Christopher 
J Gibson20, Benjamin L Ebert20, Andrew L Young21, Todd Druley22, Koichi 
Takahashi23, Nancy Gillis24,25, Markus Ball25,26, Eric Padron25, David M 
Hyman10,27, Jose Baselga28, Larry Norton10,27, Stuart Gardos10,27, Virginia M 
Klimek10,27, Howard Scher10,27, Dean Bajorin10,27, Eder Paraiso19,29, Ryma 
Benayed2, Maria E Arcila2, Marc Ladanyi2, David B Solit10,19,30, Michael F 
Berger2,19,30, Martin Tallman1, Montserrat Garcia-Closas14, Nilanjan Chatterjee31, 
Luis A Diaz Jr.10,32,33, Ross L Levine1, Lindsay M Morton14, Ahmet Zehir2,*, Elli 
Papaemmanuil3,*
Affiliations
1.Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer 
Center, 1275 York Ave, New York, NY 10065, USA
2.Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York 
Ave, New York, NY 10065, USA
3.Computational Oncology Service, Department of Epidemiology & Biostatistics, 
Center for Computational Oncology, Memorial Sloan Kettering Cancer Center, 1275 
York Ave, New York, NY 10065, USA
4.Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 
York Ave, New York, NY 10065, USA
5.Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer 
Center, 1275 York Ave, New York, NY 10065, USA
6.Department of Information Systems, Memorial Sloan Kettering Cancer Center, 
1275 York Ave, New York, NY 10065, USA
7.Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, 
1275 York Ave, New York, NY 10065, USA
8.Department of Pathology, Hematopathology Service, Memorial Sloan Kettering 
Cancer Center, 1275 York Ave, New York, NY 10065, USA
Bolton et al. Page 24













9.Department of Medicine, University of North Carolina at Chapel Hill, 321 S 
Columbia St, Chapel Hill, NC 27599, USA
10.Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York 
Ave, New York, NY 10065, USA
11.Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering 
Cancer Center, 1275 York Ave, New York, NY 10065, USA
12.Department of Health Informatics, Memorial Sloan Kettering Cancer Center, 1275 
York Ave, New York, NY 10065, USA
13.Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York 
Ave, New York, NY 10065, USA
14.Division of Cancer Epidemiology and Genetics, National Cancer Institute, 
National Institutes of Health, 9609 Medical Center Drive, MSC 9776, Bethesda, MD 
20892, USA
15.Department of Oncology, University of Cambridge, Addenbrooke’s Hospital, Hills 
Rd, Cambridge CB2 0SP, United Kingdom
16.Department of Public Health and Primary Care, University of Cambridge, 
Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, United 
Kingdom
17.Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer 
Center, 1275 York Ave, New York, NY 10065, USA
18.Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer 
Center, 1275 York Ave, New York, NY 10065, USA
19.Department of Medicine, Endocrinology Service, Memorial Sloan Kettering 
Cancer Center, 1275 York Ave, New York, NY 10065, USA
20.Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline 
Ave, Boston, MA 02215, USA
21.Department of Medicine, Washington University School of Medicine, 660 S Euclid 
Ave, St. Louis, MO 63110, USA
22.Department of Pediatrics, Washington University School of Medicine, 660 S 
Euclid Ave, St. Louis, MO 63110, USA
23.Department of Leukemia, The University of Texas MD Anderson Cancer Center, 
1515 Holcombe Blvd, Houston, TX 77030, USA
24.Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Dr, 
Tampa, FL 33612, USA
25.Department of Malignant Hematology, Moffitt Cancer Center, 12902 Magnolia Dr 
Tampa, FL 33612, USA
26.Institute of Pathology, Faculty of Medicine and University Hospital Cologne, 
University of Cologne, Kerpener Str 62, 50937 Cologne, Germany
Bolton et al. Page 25













27.Weill Cornell Medical College, 407 E 61st St, New York, NY 10065, USA
28.Research & Development, AstraZeneca, The Darwin Building, 310 Milton Rd, 
Milton, Cambridge CB4 0WG, United Kingdom
29.Center for Strategy & Innovation, Memorial Sloan Kettering Cancer Center, 1275 
York Ave, New York, NY 10065, USA
30.Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan 
Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
31.Department of Biostatistics, Bloomberg School of Public Health Department of 
Oncology, School of Medicine, Johns Hopkins University, 615 N Wolfe St, Baltimore, 
MD 21205, USA
32.Program in Precision Interception and Prevention, Memorial Sloan Kettering 
Cancer Center, 1275 York Ave, New York, NY 10065, USA
33.Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer 
Center, 1275 York Ave, New York, NY 10065, USA
ACKNOWLEDGEMENTS
This work was supported by the National Institutes of Health (K08 CA241318 to K.B., K12 CA120780 to C.C., 
P50 CA172012 to L.B., P50 CA172012 to J.F., UG1 HL069315 to V.K.), American Society of Hematology (K.B. 
and Elli Papaemmanuil), EvansMDS Foundation (K.B.), European Hematology Association (Elli Papaemmanuil), 
Gabrielle’s Angels Foundation (Elli Papaemmanuil), V Foundation (Elli Papaemmanuil), Geoffrey Beene 
Foundation (Elli Papaemmanuil), UNC Oncology Clinical Translational Research Training Program (C.C.), Cycle 
for Survival (V.K.), Starr Cancer Consortium (to R.L., A.Z., M.F.B., R.P.), and the Cancer Colorectal Cancer Dream 
Team Translational Research Grant (SU2C-AACR-DT22-17 to L.D.). Elli Papaemmanuil is a Josie Robertson 
Investigator. C.C. is a recipient of the Conquer Cancer Foundation Young Investigator Award and the Prostate 
Cancer Foundation Young Investigator Award. K.S. is a recipient of the Defense Early Investigator Research Award 
(W81XWH-18-1-0330), Prostate Cancer Foundation Young Investigator Award and the Prostate Cancer Foundation 
Challenge Award. C.L., M.G. and L.M. are supported by funds from the Intramural Research Program of the 
National Cancer Institute, National Institutes of Health. Work performed at Memorial Sloan Kettering Cancer 
Center was supported in part by the Cancer Center Support Grant (P30 CA008748). N.G.’s work was supported in 
part by the Tissue Core and Genomic Core Facilities at the H. Lee Moffitt Cancer Center & Research Institute, an 
NCI-designated Comprehensive Cancer Center (P30 CA076292). The University of Cambridge has received salary 
support in respect of PDPP from the NHS in the East of England through the Clinical Academic Reserve.
The authors declare the following competing interests: K.L.B. has received research funding from GRAIL. C.C.C. 
has received honoraria from AbbVie, Loxo, H3 Biomedicine, Medscape, Octapharma, and Pharmacyclics; has 
served as a consultant for AbbVie, Covance, Cowen & Co., and Dedham Group and has received institutional 
research funding from AROG, Gilead, Loxo, H3 Biomedicine, and Incyte. Z.S. has an immediate family member 
who holds consulting/advisory roles within the field of ophthalmology with Allergan, Adverum Biotechnologies, 
Alimera Sciences, Biomarin, Fortress Biotech, Genentech, Novartis, Optos, Regeneron, Regenxbio, and Spark 
Therapeutics. E.B. receives research funding from Celgene. D.G. is a consultant of MNM Diagnostics and has 
received honoraria for speaking and scientific advisory engagements with Celgene, Prime Oncology, Novartis, 
Illumina and Kyowa Hakko Kirin. S.L. is an employee of GRAIL. M.E.R. holds an uncompensated advisory role 
with AstraZeneca, Daiichi-Sankyo, Merck, and Pfizer and receives institutional research funding from AstraZeneca, 
AbbVie, Medivation, and Pfizer. B.L.E. has received research funding from Celgene and Deerfield. T.D. is the Chief 
Medical Officer, ArcherDX, Inc. and receives salary from and holds an ownership stake in the company. K.T. 
receives consultancy fees from Symbio Pharmaceuticals. D.M.H. has consulted for Fount, Chugai, Boehringer 
Ingelheim, AstraZeneca, Pfizer, Bayer, and Genentech/Roche; has equity in Fount; and has received research grants 
from Loxo, Bayer, Puma, and AstraZeneca. J.B. is an employee of AstraZeneca; is on the Board of Directors of 
Foghorn and is a past board member of Varian Medical Systems, Bristol‐Myers Squibb, Grail, Aura Biosciences 
and Infinity Pharmaceuticals; has performed consulting and/or advisory work for Grail, PMV Pharma, ApoGen, 
Juno, Eli Lilly, Seragon, Novartis, and Northern Biologics; has stock or other ownership interests in PMV Pharma, 
Grail, Juno, Varian, Foghorn, Aura, Infinity Pharmaceuticals, ApoGen, Northern Biologics as well as Tango and 
Venthera, for which is a co‐founder; and has previously received honoraria or travel expenses from Roche, Novartis, 
and Eli Lilly. M. Ladanyi serves on the advisory boards for Astra-Zeneca, Bristol Myers Squibb, Takeda, Bayer, 
Bolton et al. Page 26













and Merck, and has received research support from Loxo Oncology and Helsinn Therapeutics. D.B.S. has served as 
a consultant or received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Illumina and Vivideon 
Therapeutics. M.F.B. is on the advisory board for Roche and receives research support from Illumina. M.S.T. 
receives research funding from AbbVie, Cellerant, Orsenix, ADC Therapeutics, and Biosight; serves on the 
advisory boards of Daiichi-Sankyo, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, and Jazz 
Pharma; has received royalties from UpToDate; and has received research funding from Incyte, Kura Oncology, and 
Celgene. L.A.D. is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce 
Therapeutics; is a paid consultant to PGDx and Neophore; is an uncompensated consultant for Merck (with the 
exception of travel and research support for clinical trials); is an inventor of multiple licensed patents related to 
technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy from 
Johns Hopkins University, some of which are associated with equity or royalty payments directly to Johns Hopkins 
and L.A.D.; and holds equity in PGDx, Jounce Therapeutics, Thrive Earlier Detection and Neophore; his wife holds 
equity in Amgen. The terms of all these arrangements are being managed by Johns Hopkins and Memorial Sloan 
Kettering in accordance with their conflict of interest policies. R.L.L. is on the supervisory board of Qiagen and is a 
scientific advisor to Loxo, Imago, C4 Therapeutics and Isoplexis, which include equity interest; receives research 
support from and has consulted for Celgene and Roche and has consulted for Lilly, Janssen, Astellas, Morphosys 
and Novartis; and has received honoraria from Roche, Lilly and Amgen for invited lectures and from Gilead for 
grant reviews. A.Z. received honoraria from Illumina. E. Papaemmanuil receives research funding from Celgene 
and is a co-founder in Isabl Technologies, a software analytics company for high-throughput clinical whole-genome 
and RNA-sequencing analyses.
REFERENCES
1. Armitage P & Doll R The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis. 
British Journal of Cancer vol. 8 1–12 (1954). [PubMed: 13172380] 
2. Greaves M & Maley CC Clonal evolution in cancer. Nature 481, 306–313 (2012). [PubMed: 
22258609] 
3. Alexandrov LB et al. The Repertoire of Mutational Signatures in Human Cancer. 
doi:10.1101/322859.
4. Sabarinathan R et al. The whole-genome panorama of cancer drivers. doi:10.1101/190330.
5. Yates LR & Campbell PJ Evolution of the cancer genome. Nature Reviews Genetics vol. 13 795–
806 (2012).
6. Ding L et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome 
sequencing. Nature 481, 506–510 (2012). [PubMed: 22237025] 
7. Blokzijl F et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature 
538, 260–264 (2016). [PubMed: 27698416] 
8. Martincorena I et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 
911–917 (2018). [PubMed: 30337457] 
9. Martincorena I, Jones PH & Campbell PJ Constrained positive selection on cancer mutations in 
normal skin. Proceedings of the National Academy of Sciences of the United States of America vol. 
113 E1128–9 (2016).
10. Martincorena I et al. Tumor evolution. High burden and pervasive positive selection of somatic 
mutations in normal human skin. Science 348, 880–886 (2015). [PubMed: 25999502] 
11. Yokoyama A et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. 
Nature 565, 312–317 (2019). [PubMed: 30602793] 
12. Suda K et al. Clonal Expansion and Diversification of Cancer-Associated Mutations in 
Endometriosis and Normal Endometrium. Cell Reports vol. 24 1777–1789 (2018). [PubMed: 
30110635] 
13. Jaiswal S et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. 
Med. 371, 2488–2498 (2014). [PubMed: 25426837] 
14. Genovese G et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. 
N. Engl. J. Med. 371, 2477–2487 (2014). [PubMed: 25426838] 
15. McKerrell T et al. Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related 
Clonal Hemopoiesis. Cell Reports vol. 10 1239–1245 (2015). [PubMed: 25732814] 
16. Xie M et al. Age-related mutations associated with clonal hematopoietic expansion and 
malignancies. Nature Medicine vol. 20 1472–1478 (2014).
Bolton et al. Page 27













17. Fernandez-Antoran D et al. Outcompeting p53-Mutant Cells in the Normal Esophagus by Redox 
Manipulation. Cell Stem Cell 25, 329–341.e6 (2019).
18. Hsu JI et al. PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic 
Chemotherapy. Cell Stem Cell 23, 700–713.e6 (2018).
19. Wong TN et al. Role of TP53 mutations in the origin and evolution of therapy-related acute 
myeloid leukaemia. Nature 518, 552–555 (2015). [PubMed: 25487151] 
20. Abelson S et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559, 
400–404 (2018). [PubMed: 29988082] 
21. Desai P et al. Somatic Mutations Predict Acute Myeloid Leukemia Years Before Diagnosis. 
doi:10.1101/237941.
22. Morton LM et al. Evolving risk of therapy-related acute myeloid leukemia following cancer 
chemotherapy among adults in the United States, 1975–2008. Blood 121, 2996–3004 (2013). 
[PubMed: 23412096] 
23. McNerney ME, Godley LA & Le Beau MM Therapy-related myeloid neoplasms: when genetics 
and environment collide. Nature Reviews Cancer vol. 17 513–527 (2017). [PubMed: 28835720] 
24. Coombs CC et al. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic 
Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell 21, 374–
382.e4 (2017).
25. Chakravarty D et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017, 
(2017).
26. Papaemmanuil E et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. 
J. Med. 365, 1384–1395 (2011). [PubMed: 21995386] 
27. Papaemmanuil E et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. 
Engl. J. Med. 374, 2209–2221 (2016). [PubMed: 27276561] 
28. Grinfeld J et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N. 
Engl. J. Med. 379, 1416–1430 (2018). [PubMed: 30304655] 
29. Bick AG et al. Inherited Causes of Clonal Hematopoiesis of Indeterminate Potential in TOPMed 
Whole Genomes. bioRxiv 782748 (2019) doi:10.1101/782748.
30. Abelson S et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature 559, 
400–404 (2018). [PubMed: 29988082] 
31. McNerney ME, Godley LA & Le Beau MM Therapy-related myeloid neoplasms: when genetics 
and environment collide. Nature Reviews Cancer vol. 17 513–527 (2017). [PubMed: 28835720] 
32. Lindsley RC et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. 
Blood 125, 1367–1376 (2015). [PubMed: 25550361] 
33. Welch JS et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–
278 (2012). [PubMed: 22817890] 
34. Cancer Genome Atlas Research Network et al. Genomic and epigenomic landscapes of adult de 
novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013). [PubMed: 23634996] 
35. Gillis NK et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: 
a proof-of-concept, case-control study. Lancet Oncol. 18, 112–121 (2017). [PubMed: 27927582] 
36. Takahashi K Germline polymorphisms and the risk of therapy-related myeloid neoplasms. Best 
Pract. Res. Clin. Haematol. 32, 24–30 (2019). [PubMed: 30927971] 
37. Gibson CJ et al. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous 
Stem-Cell Transplantation for Lymphoma. J. Clin. Oncol. 35, 1598–1605 (2017). [PubMed: 
28068180] 
38. Young AL, Tong RS, Birmann BM & Druley TE Clonal haematopoiesis and risk of acute myeloid 
leukemia. Haematologica (2019) doi:10.3324/haematol.2018.215269.
39. Fianchi L et al. Characteristics and outcome of therapy-related myeloid neoplasms: Report from 
the Italian network on secondary leukemias. Am. J. Hematol. 90, E80–5 (2015). [PubMed: 
25653205] 
40. Choudhury PP et al. iCARE: R package to build, validate and apply absolute risk models. 
doi:10.1101/079954.
Bolton et al. Page 28













41. Maas P et al. Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White 
Women in the United States. JAMA Oncol 2, 1295–1302 (2016). [PubMed: 27228256] 
42. Candido Dos Reis FJ et al. An updated PREDICT breast cancer prognostication and treatment 
benefit prediction model with independent validation. Breast Cancer Res. 19, 58 (2017). [PubMed: 
28532503] 
43. Meng A, Wang Y, Van Zant G & Zhou D Ionizing radiation and busulfan induce premature 
senescence in murine bone marrow hematopoietic cells. Cancer Res. 63, 5414–5419 (2003). 
[PubMed: 14500376] 
44. Hu W et al. Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib 
and its Differentiation from Cytotoxic Chemotherapies. Clin. Cancer Res. 22, 2000–2008 (2016). 
[PubMed: 26631614] 
45. Meisel M et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. 
Nature 557, 580–584 (2018). [PubMed: 29769727] 
46. Zhu M et al. Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic 
Liver Disease. Cell 177, 608–621.e12 (2019).
METHODS-ONLY REFERENCES
47. Cheng DT et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer 
Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical 
Assay for Solid Tumor Molecular Oncology. J. Mol. Diagn. 17, 251–264 (2015). [PubMed: 
25801821] 
48. Schmieder R & Edwards R Quality control and preprocessing of metagenomic datasets. 
Bioinformatics 27, 863–864 (2011). [PubMed: 21278185] 
49. Tate JG et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 47, 
D941–D947 (2019). [PubMed: 30371878] 
50. Papaemmanuil E et al. Identification of Novel Somatic Mutations in SF3B1, a Gene Encoding a 
Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts and 
Other Common Cancers. European Journal of Cancer vol. 47 7 (2011).
51. Campo E et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (IARC 
Who Classification of Tum, 2017).
52. Wolff AC et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national 
comprehensive cancer network experience. J. Clin. Oncol. 33, 340–348 (2015). [PubMed: 
25534386] 
53. Website. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969–2017) 
(www.seer.cancer.gov/popdata), National Cancer Institute, DCCPS, Surveillance Research 
Program, released December 2018.
Bolton et al. Page 29













Figure 1. Specific molecular subtypes of CH-PD correlate with age, prior therapy exposure and 
smoking history.
(A) Proportion of patients with CH-PD mutations in specific genes among treated and 
untreated patients. Multivariable logistic regression was used to test whether the odds of 
having a specific gene mutated differed between treated (n=5,978) and untreated (n=4,160) 
patients after adjustment for age, gender, smoking and ethnicity. * p<0.05, ** p<0.01, *** 
p<0.001 (B) Among patients with CH-PD, the proportion with mutations in specific genes, 
by age group and treatment status. (C) Odds ratio with 95% confidence interval for CH-PD 
mutation in the ten most commonly mutated genes with top, increasing age (n=10,138); 
middle, for patients previously exposed to cancer therapy (n=5,978) compared to those with 
no exposure (n=4160); bottom, for current/former smokers (n=4,989) compared to non-
smokers (n=5,145) in multivariable logistic regression models adjusted for therapy, smoking, 
ethnicity, age, gender and time from diagnosis to blood draw. *, q-value (FDR-corrected p-
value) <0.05, ** q<0.01, *** q<0.001. Age is expressed as the mean centered values.
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Figure 2. Association between CH-PD and prior exposure to cancer therapy.
(A) Odds ratios (OR) and 95% confidence intervals for CH-PD and specific classes of 
cancer therapy in multivariable logistic regression adjusted for each other, smoking, 
ethnicity, gender and time from diagnosis to blood draw. Top, OR for broad classes of cancer 
therapy; middle. OR between CH-PD and prior exposure to subclasses of cytotoxic therapy; 
bottom, OR between CH-PD and exposure to specific platinum-based drugs. (B) OR 
between prior receipt of cancer therapy and CH-PD stratified by tertile of cumulative 
exposure for the agent. Multivariable logistic regression was used adjusted as in (A) but with 
cumulative weight-adjusted dose of systemic therapy classes and cumulative radiation dose 
(as expressed in EQD2. The p-trend was calculated to test for association between CH and 
increasing tertiles of cumulative cancer therapy exposure among those who received the 
therapy in the multivariable model. Shaded bands indicate 95% confidence intervals. (C) 
Heatmap showing the log(OR) between CH-PD in specific genes and prior exposure to the 
major classes of cytotoxic therapy and radiation therapy in logistic regression models 
adjusted for therapy subclass, smoking, ethnicity, gender and time from diagnosis to blood 
draw. * q (FDR-corrected p-value) <0.05, ** q<0.01, *** q<0.001.
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Figure 3. Clonal evolution of CH mutations under the selective pressure of cancer therapy.
(A) Change in VAF for CH mutations from initial to follow-up sequencing for patients 
stratified by type of therapy received during the follow-up period. XRT, external beam 
radiation. (B) Change in growth rate for DDR and non-DDR CH mutations among those 
who received XRT (n=167) or cytotoxic therapy (n=285) during the follow-up period. 
Shown are the p-values generated from t-tests comparing the growth rate of CH mutations 
among patients exposed to either of these therapies compared to untreated patients. (C) 
Change in growth rate for specific CH mutations stratified by whether patients received 
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cytotoxic or radiation therapy (n=268) or no therapy (n=177) during the follow-up period. 
Shown are the FDR-corrected p-values (q-value) from a t-test comparing the growth rate of 
mutations in treated and untreated patients. (D) Change in growth rate for DDR and non-
DDR CH mutations stratified by tertile of cumulative exposure to cytotoxic therapy and 
XRT. Shown are the p-values for a trend test for increasing growth rate of CH with 
increasing tertile of therapy exposure using generalized linear regression adjusted for age, 
gender and smoking. Shaded bands indicate interquartile ranges. Intra-subject competition 
between DDR and non-DDR CH mutations. Connecting lines show the difference in growth 
rate between DDR vs. other genes in patients who received XRT or cytotoxic therapy vs. 
those who did not receive such therapy during the follow-up period. A paired t-test was used 
to test for significance in the difference between growth rates of DDR and non-DDR CH 
mutations within individuals. All p-values are two-sided.
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Figure 4. Risk of AML or MDS by clinical and CH-PD mutational characteristics in patients 
with solid tumors.
(A) Hazard ratio and 95% confidence intervals from Cox regression for blood count indexes, 
and CH-PD mutational characteristics for therapy-related myeloid neoplasms (tMN; AML 
or MDS, n=75). All models were adjusted for age and gender and stratified by study center. 
Blood counts are expressed as the mean centered score (the OR is per 1 SD of the blood 
count). * p<0.05, ** p<0.01, *** p<0.001. (B) Projected distribution of absolute 10-year risk 
of AML or MDS for women after a breast cancer diagnosis in the United States aged 50–75 
at presentation based on our synthetic model. (C) Comparison of distribution of absolute 10-
year risk of AML or MDS among women at the top percentiles of risk between those who 
go on to receive adjuvant cytotoxic chemotherapy and those who receive surgery only. 
n=9,437.
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